ObjectivesTo investigate the efficacy of multi-parametric MRI-based radiomics nomograms for preoperative distinction between benign and malignant sinonasal tumors.MethodsData of 244 patients with sinonasal tumor (training set, n=192; test set, n=52) who had undergone pre-contrast MRI, and 101 patients who underwent post-contrast MRI (training set, n=74; test set, n=27) were retrospectively analyzed. Independent predictors of malignancy were identified and their performance were evaluated. Seven radiomics signatures (RSs) using maximum relevance minimum redundancy (mRMR), and the least absolute shrinkage selection operator (LASSO) algorithm were established. The radiomics nomograms, comprising the clinical model and the RS algorithms were built: one based on pre-contrast MRI (RNWOC); the other based on pre-contrast and post-contrast MRI (RNWC). The performances of the models were evaluated with area under the curve (AUC), calibration, and decision curve analysis (DCA) respectively.ResultsThe efficacy of the clinical model (AUC=0.81) of RNWC was higher than that of the model (AUC=0.76) of RNWOC in the test set. There was no significant difference in the AUC of radiomic algorithms in the test set. The RS-T1T2 (AUC=0.74) and RS-T1T2T1C (RSWC, AUC=0.81) achieved a good distinction efficacy in the test set. The RNWC and the RNWOC showed excellent distinction (AUC=0.89 and 0.82 respectively) in the test set. The DCA of the nomograms showed better clinical usefulness than the clinical models and radiomics signatures.ConclusionsThe radiomics nomograms combining the clinical model and RS can be accurately, safely and efficiently used to distinguish between benign and malignant sinonasal tumors.
BackgroundSinonasal malignant tumors (SNMTs) have a high recurrence risk, which is responsible for the poor prognosis of patients. Assessing recurrence risk in SNMT patients is a current problem.PurposeTo establish an MRI‐based radiomics nomogram for assessing relapse risk in patients with SNMT.Study TypeRetrospective.PopulationA total of 143 patients with 68.5% females (development/validation set, 98/45 patients).Field Strength/SequenceA 1.5‐T and 3‐T, fat‐suppressed fast spin echo (FSE) T2‐weighted imaging (FS‐T2WI), FSE T1‐weighted imaging (T1WI), and FSE contrast‐enhanced T1WI (T1WI + C).AssessmentThree MRI sequences were used to manually delineate the region of interest. Three radiomics signatures (T1WI and FS‐T2WI sequences, T1WI + C sequence, and three sequences combined) were built through dimensional reduction of high‐dimensional features. The clinical model was built based on clinical and MRI features. The Ki‐67‐based and tumor‐node‐metastasis (TNM) model were established for comparison. The radiomics nomogram was built by combining the clinical model and best radiomics signature. The relapse‐free survival analysis was used among 143 patients.Statistical TestsThe intraclass/interclass correlation coefficients, univariate/multivariate Cox regression analysis, least absolute shrinkage and selection operator Cox regression algorithm, concordance index (C index), area under the curve (AUC), integrated Brier score (IBS), DeLong test, Kaplan–Meier curve, log‐rank test, optimal cutoff values. A P value < 0.05 was considered statistically significant.ResultsThe T1 + C‐based radiomics signature had best prognostic ability than the other two signatures (T1WI and FS‐T2WI sequences, and three sequences combined). The radiomics nomogram had better prognostic ability and less error than the clinical model, Ki‐67‐based model, and TNM model (C index, 0.732; AUC, 0.765; IBS, 0.185 in the validation set). The cutoff values were 0.2 and 0.7 and then the cumulative risk rates were calculated.Data ConclusionA radiomics nomogram for assessing relapse risk in patients with SNMT may provide better prognostic ability than the clinical model, Ki‐67‐based model, and TNM model.Evidence Level3.Technical EfficacyStage 5.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.